Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort

Urology

Volumn 73, Issue 6, 2009, Pages 1323-1327

  Capitanio, Umberto ^a,b   Perrotte, Paul ^c   Zini, Laurent ^a   Suardi, Nazareno ^a,b   Antebi, Elie ^c   Cloutier, Vincent ^a,c   Jeldres, Claudio ^a,c   Shariat, Shahrokh F ^a   Duclos, Alain ^c   Arjane, Philippe ^c   Saad, Fred ^c   Montorsi, Francesco ^b   Karakiewicz, Pierre I ^a,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANADA; CANCER SCREENING; CLINICAL EXAMINATION; COHORT ANALYSIS; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; POPULATION DISTRIBUTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 67349114825     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.10.026     Document Type: Article

References (30)

1. Carter H.B. Prostate cancers in men with low PSA levels-must we find them?. N Engl J Med 350 (2004) 2292-2294
2. Ross K.S., Carter H.B., Pearson J.D., et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 284 (2000) 1399-1405
3. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
4. Labrie F., Candas B., Cusan L., et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59 (2004) 311-318
5. Fang J., Metter E.J., Landis P., et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology 58 (2001) 411-416
6. Schroder F.H., van der Cruijsen-Koeter I., de Koning H.J., et al. Prostate cancer detection at low prostate specific antigen. J Urol 163 (2000) 806-812
7. Lodding P., Aus G., Bergdahl S., et al. Characteristics of screening detected prostate cancer in men 50-66 years old with 3-4 ng/ml prostate specific antigen. J Urol 159 (1998) 899-903
8. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
9. Bjartell A. PSA and prostate cancer screening: the challenge of the new millennium. Eur Urol 52 (2007) 1284-1286
10. Roemeling S., Roobol M.J., de Vries S.H., et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51 (2007) 1244-1251
11. Shariat S.F., and Karakiewicz P.I. Screening for prostate cancer in 2007: the PSA era and its challenges are not over. Eur Urol 53 (2008) 457-460
12. Avery K.N., Blazeby J.M., Lane J.A., et al. Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. Eur Urol 53 (2008) 1186-1193
13. Loeb S., Roehl K.A., Antenor J.A., et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67 (2006) 316-320
14. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
15. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452-1455
16. Horninger W., Cheli C.D., Babaian R.J., et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2-4 nanograms per milliliter. Urology 60 (2002) 31-35
17. Tanguay S., Begin L.R., Elhilali M.M., et al. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 59 (2002) 261-265
18. Chun F.K., Graefen M., Briganti A., et al. Initial biopsy outcome prediction-head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 51 (2007) 1236-1243
19. Karakiewicz P.I., Benayoun S., Kattan M.W., et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 173 (2005) 1930-1934
20. Chun F.K., Hutterer G.C., Perrotte P., et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int 100 (2007) 37-41
21. Capitanio U., Scattoni V., Freschi M., et al. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol 54 (2008) 118-125
22. Chun F.K., Suardi N., Capitanio U., et al. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. Eur Urol (2008 May 15) Epub
23. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
24. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335 (1996) 304-310
25. Lilja H., Ulmert D., Bjork T., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years. J Clin Oncol 25 (2007) 431-436
26. Vickers A.J., Ulmert D., Serio A.M., et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 121 (2007) 2212-2217
27. Postma R., Schroder F.H., van Leenders G.J., et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam: a comparison of two rounds of screening. Eur Urol 52 (2007) 89-97
28. van den Bergh R.C., Roobol M.J., Wolters T., et al. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU Int (2008 Aug 18) Epub
29. Oesterling J.E., Jacobsen S.J., Klee G.G., et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154 (1995) 1090-1095
30. Uzzo R.G., Pinover W.H., Horwitz E.M., et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. Urology 61 (2003) 754-759